The FDA announced that it approved Incyte (INCY) Corporation’s tafasitamab-cxix with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, FL.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Positive Buy Rating for Incyte Driven by Promising INCA33989 Trial Results and Favorable Safety Profile
- Sarepta suspends Elevidys shipments, Supernus acquires Sage: Morning Buzz
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- Video: Sarepta, Hinge Health among major pre-market movers
- Incyte’s Strategic and Financial Challenges Prompt Sell Rating Despite Promising Trial Data